C4 Therapeutics to Present Preliminary Monotherapy Data From the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics to Present Preliminary Monotherapy Data From the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.
2024年7月16日，馬薩諸塞州沃特敦市（GLOBE NEWSWIRE）——C4 Therapeutics，Inc.（C4T）（納斯達克：CCCC）是一家臨床階段的生物製藥公司，致力於推進靶向蛋白降解科學的發展。今天，該公司宣佈，正在進行的CFT1946一期/二期臨床試驗單藥劑量遞增部分的初步數據，將作爲迷你口頭報告在2024年9月13日至17日於西班牙巴塞羅那舉行的歐洲醫學腫瘤學會（ESMO）2024年大會上發佈，該藥是一種面向突變BRAF V600實體腫瘤的新型BiDAC降解劑。
Details of the presentation are as follows:
演示的詳細信息如下:
Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: Saturday, September 14, 2024, 2:45 – 2:50 CEST
Final Publication Number: 612MO
Session Category: Mini oral session
Session Title: Developmental therapeutics
Location: Oviedo Auditorium – Hall 3
Presenter: Maria Vieito, M.D., Msc (Barcelona, Spain, La Coruña)
標題：CFT1946一項治療突變BRAF V600實體腫瘤的一期研究的初步結果
演示日期和時間：2024年9月14日，中歐夏令時2:45-2:50
最終出版號：612MO
會議類別：迷你口頭會話
會議標題：發展性治療
地點：奧維耶多禮堂-3號廳
演講者：Maria Vieito萬.D.，Msc（西班牙，拉科魯尼亞，巴塞羅那）
About C4 Therapeutics
關於C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit .
C4 Therapeutics（C4T）（納斯達克： CCCC）是一家臨床前期製藥公司，致力於通過有針對性的蛋白質降解科學來創造變革患者生命的新一代藥物。C4T正在通過臨床研究推進針對腫瘤的有針對性計劃，並利用其TORPEDO平台來高效地設計和優化小分子藥物來治療難治性疾病。C4T的蛋白質降解藥物旨在利用人體天然的蛋白質回收系統，快速降解引起疾病的蛋白質，有望克服藥物耐受性，克服難以治療的靶點並改善患者預後。要獲得更多信息，請訪問 .
About CFT1946
關於CFT1946
CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant targets. In preclinical studies, CFT1946 is active in vivo and in vitro in models with BRAF V600E driven disease and in models resistant to BRAF inhibitors. CFT1946 is currently in a Phase 1 dose escalation study in BRAF V600X mutant solid tumors including colorectal cancer, melanoma and non-small cell lung cancer. More information about this trial may be accessed at (identifier: NCT05668585).
CFT1946是一種口服可用的BiDAC降解劑，旨在對BRAF V600X突變靶點進行強力和選擇性瞄準。在臨床前研究中，CFT1946在對BRAF V600E驅動疾病和對BRAF抑制劑具有抗藥性的模型中，體內外均表現活性。CFT1946目前正在進行一項BRAF V600X突變實體瘤包括結直腸癌、黑色素瘤和非小細胞肺癌的一期劑量遞增研究。有關此試驗的更多信息可在網址（標識符：NCT05668585）上獲得。
Contacts:
聯繫人：
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
投資者：
Courtney Solberg
投資者關係高級經理
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
媒體:
Loraine Spreen
董事高級負責人，公司通信和患者倡導。
LSpreen@c4therapeutics.com